FE/HE NEWS
University of Edinburgh appoints new CEO of Edinburgh Innovations
The University of Edinburgh has announced the permanent appointment of Dr Andrea Taylor as the new Chief Executive Officer of Edinburgh Innovations, the University’s commercialisation service. Dr Taylor brings over 25 years’ experience working across the innovation sector holding positions in academia, the pharmaceuticals sector, biotech, commercial deal making, inward investment and economic development.
Andrea has worked in Edinburgh Innovations for six years, more recently as Director of Strategic Partnerships before stepping in as Interim CEO. Andrea has had particular success securing high profile
international partnerships such as NEURii, to tackle dementia, and beLAB1407, to advance drug discovery.
Dr Andrea Taylor, Chief Executive Officer of EI, said: “I am delighted to be given the opportunity to lead Edinburgh Innovations into an exciting and bold next phase of its journey. Entrepreneurship, partnership and internationalisation are critical elements of the University of Edinburgh’s recently published Research and Innovation strategy, and Edinburgh Innovations will play a pivotal role supporting the University to achieve even greater innovation success. Unlocking technology, building impactful companies and partnering internationally will all be key areas of focus.” Since joining Edinburgh Innovations in 2017, Andrea has played a key role in driving innovation at Edinburgh Innovations and the University, growing industrial and translational research income to almost £92 million. Last year, 123 companies were launched and £107.6 million was invested into the University’s portfolio via in- house venture investment team, Old College Capital.
Heriot-Watt University signs deal to accelerate cutting-edge medical research
research from its campuses in Scotland, Dubai and Malaysia. The ABHI is the UKs leading industry association for health technology whose members supply products from syringes and wound dressings to surgical robots, diagnostics and digitally enhanced technologies. It represents the industry to stakeholders, such as the government, NHS and regulators.
The MoU will see the two bodies work together to increase the profile of Heriot-Watt as a hub of academic excellence. The collaboration will take a “triple helix” approach, engaging academia, health systems, and industry partners throughout Scotland and the UK with a commitment to understanding the challenges innovators face in HealthTech research and commercialisation, working to identify opportunities to overcome them through supported processes and policy lobbying.
Heriot-Watt University has signed a Memorandum of Understanding with the Association of British HealthTech Industries (ABHI) which will see the two collaborate to advance medical research and development. Working with over 150 academics in the university’s new Global Research Institute in Health and Care Technologies, the ABHI will leverage its existing relationships with both multinational and small and medium sized companies to nurture an industry-wide spirit of co- creation.
Health and Care Technologies at Heriot-Watt works to turn cutting-edge research into impactful and practical solutions to make a positive impact on peoples’ lives, the NHS and health and care globally, developing
18
www.education-today.co.uk
HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. The sector is the largest employer in the broader Life Sciences industry, employing 154,000 people in 4,465 companies, with a combined turnover of £34.3bn. The industry has enjoyed growth of around 5% in recent years and the ABHI’s 400 members account for approximately 80% of the sector by value.
Steve McLaughlin, Vice Principal and Provost at Heriot-Watt University said: “This collaboration is an important step in advancing our global research in health and care technology solutions. We will work together to co-develop research, address regulation, enhance data and insight, while meticulously championing patient privacy and protection.”
July/August 2024
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
